Request a Quote
CASE STUDY

SHARE THIS

Awareness Campaign for Recurrent Anaplastic Astrocytoma

A clinical trial was recruiting patients with recurrent Anaplastic Astrocytoma (AA), a grade 3 glioma. The study was being conducted across the US as well as in a number of European countries. AA affects about 5-8 per 100,000 people, and in order to qualify these patients must be experiencing their first recurrence or progression after surgical resection or chemotherapy treatment.

 
SHARE THIS


Subscribe to our newsletter

For the latest news & resources, sign up for our monthly newsletter.

I am a



Thank you for subscribing!

Something wrong, please try again!

ClinEdge (en-US)//www.instagram.com/clin_edge//www.facebook.com/clinedge//twitter.com/clinedge//www.linkedin.com/company/clinedgehttps://clin-edge.com/img/Elligo-2020-Master-Icon-Alt-2.png+18574960054info@clin-edge.comsales ClinEdge (en-US)Accelerating Clinical TrialsHomehttps://clin-edge.comCaseshttps://clin-edge.com/caseshttps://clin-edge.com/cases/awareness-campaign-for-recurrent-anaplastic-astrocytoma